SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after reports surfaced of a potential partnership with Novo Nordisk to distribute GLP-1 obesity drugs, signaling an end to their prior legal dispute. This development has ignited fervent community discussion about a massive short squeeze due to the stock's high short interest and its strengthened position in the digital health market.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, widely seen as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, coupled with high anticipation for a late-breaking Phase 3 data presentation at a major medical conference, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending after forming a partnership with Hims & Hers to distribute its obesity drugs, ending a prior feud and surprising the community. This, alongside reports of rapidly accelerating oral Wegovy prescriptions and an FDA crackdown on compounded GLP-1s, is driving discussion that the stock is oversold despite ongoing competitive dynamics with Eli Lilly.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure NV is surging on high volume as the community speculates a massive short squeeze and a bullish sentiment shift, following news of a key FDA official's impending departure, which is seen as favorable for gene therapies like QURE's Huntington's therapy. This is amplified by discussions of a newly clarified, less burdensome regulatory path for their lead asset and a technical rebound from oversold conditions.

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Savara Inc

Savara is trending following the FDA's Day 74 Letter confirming MOLBREEVI's Biologics License Application is under full review with a PDUFA target action date of August 22, 2026, and no advisory committee meeting planned. The community sees this as a positive step towards Molbreevi becoming a first-in-class therapy for autoimmune PAP, fueling optimism around its market potential and future valuation.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as escalating U.S.-Iran tensions have severely disrupted oil tanker traffic through the Strait of Hormuz, propelling crude prices higher. The community is split between calls for further parabolic gains to $150-$200 due to broken supply chains and warnings of a manipulated "blow-off top" and imminent correction, with broader concerns about inflation.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as its CEO hints at "curative outcomes" for AML, sparking community excitement about groundbreaking efficacy and a potential short squeeze, with further anticipation from an ongoing oncology summit. The prolonged duration of its pivotal REGAL trial, indicating patients are living longer than expected, reinforces investor belief in the drug's transformative potential beyond disease management.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is trending amidst heightened market uncertainty driven by Federal Reserve policy, geopolitical developments, and ongoing debates about the sustainability of valuations in the tech sector. Despite some community calls for a significant correction, many investors continue to favor VOO for its broad market exposure and long-term stability.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is driving intense conversation, fueled by fresh reports of potential Nvidia chip exports to China and strong AI demand outlooks from semiconductor giants, though community sentiment is sharply divided. While many view the sector as an unstoppable "infinite money glitch" in the AI boom, others warn of an impending "bubble" due to stretched valuations and recent underperformance against software ETFs.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics Holdings is trending due to recent mixed earnings results showing revenue growth but sparking community concerns about financial stability and potential dilution, even as its "game-changing" 365-day CGM system gains regulatory approvals and integrates with automated insulin delivery. This creates intense shareholder debate, with many praising the superior technology while criticizing management's ability to effectively commercialize the product and questioning the company's long-term strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why Cincinnati Financial (CINF) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

PLMR Stock Outperforms Industry: Time to Add it for Better Returns?

Palomar Holdings rides on a fee-based platform, rising crop premiums, Surety expansion, and a debt-free balance sheet backed by a strong reinsurance strategy.

Elo Mutual Pension Insurance Co Purchases New Shares in Cincinnati Financial Corporation $CINF

Elo Mutual Pension Insurance Co acquired a new stake in Cincinnati Financial Corporation (NASDAQ:CINF - Free Report) in the 3rd quarter, according to the company in its most recent filing with the...

20,000 Shares in Cincinnati Financial Corporation $CINF Bought by Strive Asset Management LLC

Strive Asset Management LLC acquired a new stake in shares of Cincinnati Financial Corporation (NASDAQ:CINF - Free Report) during the third quarter, according to its most recent Form 13F filing with...

Erste Asset Management GmbH Has $701,000 Stock Holdings in Cincinnati Financial Corporation $CINF

Erste Asset Management GmbH trimmed its position in Cincinnati Financial Corporation (NASDAQ:CINF - Free Report) by 66.0% during the third quarter, according to its most recent 13F filing with the...

Bahl & Gaynor Inc. Acquires 37,321 Shares of Cincinnati Financial Corporation $CINF

Bahl & Gaynor Inc. increased its stake in Cincinnati Financial Corporation (NASDAQ:CINF - Free Report) by 3.2% during the third quarter, according to the company in its most recent 13F filing with...

Andra AP fonden Makes New Investment in Cincinnati Financial Corporation $CINF

Andra AP fonden bought a new position in shares of Cincinnati Financial Corporation (NASDAQ:CINF - Free Report) in the third quarter, according to the company in its most recent 13F filing with the...

Mitsubishi UFJ Asset Management Co. Ltd. Buys 17,724 Shares of Cincinnati Financial Corporation $CINF

Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Cincinnati Financial Corporation (NASDAQ:CINF - Free Report) by 5.4% in the 3rd quarter, according to its most recent 13F...

JPMorgan Chase & Co. Sells 16,096 Shares of Cincinnati Financial Corporation $CINF

JPMorgan Chase & Co. lowered its position in shares of Cincinnati Financial Corporation (NASDAQ:CINF - Free Report) by 4.1% in the third quarter, according to the company in its most recent...

Citigroup Inc. Purchases 22,612 Shares of Cincinnati Financial Corporation $CINF

Citigroup Inc. lifted its position in shares of Cincinnati Financial Corporation (NASDAQ:CINF - Free Report) by 14.3% during the 3rd quarter, according to its most recent filing with the Securities...

Cincinnati Financial Corp. engages in providing property casualty and life insurance services. It operates through the following segments: Commercial Lines Insurance, Personal Lines Insurance, Excess and Surplus Lines Insurance, Life Insurance, and Investments. The Commercial Lines Insurance segment includes commercial casualty, commercial property, commercial auto, worker's compensation, and other commercial lines insurance. The Personal Lines Insurance segment manages personal auto, homeowner, and other personal lines insurance. The Excess and Surplus Lines Insurance segment covers business risks such as the nature of the business or its claim history, that are difficult to profitably insure in the standard commercial lines market. The Life Insurance segment offers term life insurance, universal life insurance, worksite products, and whole life insurance services. The Investment segment generates revenue from the fixed-maturity investment and equity investment. The company was founded by John Jack Schiff Sr., Robert Cleveland Schiff, and Harry M. Turner in 1968 and is headquartered in Fairfield, OH.

CINF
Cincinnati Financial Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CINF News

CINFCincinnati Financial Corp.